Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab Alone or With Cobolimab in Resectable Stage III or Oligometastatic Stage IV Melanoma
NCT04139902Phase 2Active, not recruiting
- Start
- Jun 2020
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cobolimab in melanoma (2 arms). Primary endpoint: Major Pathologic Response. Started Jun 2020; status: active, not recruiting.
02
Drugs
cobolimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04139902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139902.